Completed NCT06572449
This study is completed in the United States. It is testing Slowly Increasing Dose and Food Effect of KarXT for schizophrenia.
Multiple locations, including Los Alamitos Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 65 Years
Countries United States
Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition Schizophrenia Completed NCT00228540
This study is completed in the United States. It is testing satisfaction With Modafinil Treatment for ADHD.
Multiple locations, including Scottsdale ADHD Drug From 6 Years to 17 Years
Countries United States
Sponsor Cephalon
Condition ADHD Completed NCT00501865
This study is completed in the United Kingdom. It is testing Effect of Food on the Concentration of GW273225 for Bipolarity.
In Cambridge Bipolarity Drug From 18 Years to 55 Years
Countries United Kingdom
Sponsor GlaxoSmithKline
Condition Bipolarity Completed NCT06058039
This study is completed in the United States, in France, in Bulgaria, .... It is testing Effects of Oral NMRA-335140 for depression.
Multiple locations, including Cerritos Depression Drug From 18 Years to 65 Years
Countries United States, France, Bulgaria, ...
Sponsor Neumora Therapeutics, Inc.
Condition Depression Completed NCT06058013
This study is completed in the United States, in Canada, in Brazil, .... It is testing Effects of Oral NMRA-335140 for depression.
Multiple locations, including Encino Depression Drug From 18 Years to 65 Years
Countries United States, Canada, Brazil, ...
Sponsor Neumora Therapeutics, Inc.
Condition Depression Completed NCT05203341
This study is completed in the United States, in Bulgaria, in Czechia, .... It is testing NBI-1065845 for depression.
Multiple locations, including Birmingham Depression Drug From 18 Years to 65 Years
Countries United States, Bulgaria, Czechia, ...
Sponsor Neurocrine Biosciences
Condition Depression Completed NCT00921804
This study is completed in the United States. It is testing Efficacy, Safety, and Tolerability of AZD8529 for schizophrenia.
Multiple locations, including Garden Grove Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor AstraZeneca
Condition Schizophrenia Active Not Recruiting NCT06029439
This study is active but not recruiting in the United States, in France, in Canada, .... It focuses on Depression.
Multiple locations, including Huntsville Depression Drug From 18 Years to 65 Years
Countries United States, France, Canada, ...
Sponsor Neumora Therapeutics, Inc.
Condition Depression Completed NCT00334880
This study is completed in the United States. It is testing Safety and Efficacy of NRP104 for ADHD.
Multiple locations, including Little Rock ADHD Drug From 18 Years to 55 Years
Countries United States
Sponsor New River Pharmaceuticals
Condition ADHD Completed NCT02184767
This study is completed in the United States. 5, 5, or 10 mg for Bipolarity.
Multiple locations, including Atlanta Bipolarity Drug From 10 Years to 17 Years
Countries United States
Sponsor Teva Branded Pharmaceutical Products R&D, Inc.
Condition Bipolarity Completed NCT04972227
This study is completed in the United States. It is testing Safety and Pharmacokinetics of CY6463 for schizophrenia.
Multiple locations, including Long Beach Schizophrenia Drug From 18 Years to 50 Years
Countries United States
Sponsor Tisento Therapeutics
Condition Schizophrenia Completed NCT02411695
This study is completed in the United States. It is testing Brexpiprazole (OPC- 34712) for schizophrenia.
Multiple locations, including Little Rock Schizophrenia Drug From 13 Years to 17 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Schizophrenia